NCT04098744 - Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2020

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions

CIN 2/3HPV InfectionPre-Cancerous DysplasiaCervical DysplasiaHPV Related Disease

Interventions

DRUG

Artesunate vaginal insert

Artesunate formulated as vaginal inserts, 200mg

DRUG

Placebo vaginal insert

Placebo for artesunate vaginal inserts

Trial Locations (7)

RECRUITING

Florida Gynecologic Oncology, Fort Myers

RECRUITING

Cleveland Clinic Fairview Hospital, Cleveland

RECRUITING

Hillcrest Hospital, Mayfield Heights

RECRUITING

Cleveland Clinic Foundation, Cleveland

RECRUITING

University of Michigan, Ann Arbor

RECRUITING

The Harris Health System (L.B.J Hospital), Houston

RECRUITING

University of Texas, M.D. Anderson, Houston